参考文献/References:
［1］ FEIGIN V L,FOROUZANFAR M H,KRISHNAMURTHI R,et al.Global and regional burden of stroke during 1990-2010:findings from the Global Burden of Disease Study 2010［J］.Lancet (London，England),2014,383(9913):245-254.
［2］ ZHOU H，ZHANG X,LU J.Progress on diabetic cerebrovascular diseases［J］.Bosn J Basic Med Sci，2014，14(4):185-190.
［3］ PHASHA M N，SOMA P，PRETORIUS E，et al.Coagulopathy in type 2 diabetes mellitus:pathological mechanisms and the role of factor XⅢ-A single nucleotide polymorphisms［J］.Curr Diabetes Rev，2019，15(6):446-455.
［4］ ROSS S，GERSTEIN H,PARE G.The genetic link retween diabetes and atherosclerosis［J］.Can J Cardiol，2018，34(5):565-574.
［5］ LUSIS A J.Atherosclerosis［J］.Nature，2000，407(6801):233-241.
［6］ ROSS R.Atherosclerosis：an inflammatory disease［J］.N Engl J Med，1999，340(2):115-126.
［7］ JIN P,CONG S.LOX-1 and atherosclerotic-related diseases［J］.Clin Chim Acta，2019，491:24-29.
［8］ KATAKAMI N.Mechanism of development of atherosclerosis and cardiovascular disease in diabetes mellitus［J］.J Atheroscler Thromb，2018，25(1):27-39.
［9］ DAVIS F M,GALLAGHER K.Epigenetic mechanisms in monocytes/macrophages regulate inflammation in cardiometabolic and vascular disease［J］.Arterioscler Thromb Vasc Biol，2019，39(4):623-634.
［10］ PILELY K，BAKKE S S，PALARASAH Y，et al.Alpha-cyclodextrin inhibits cholesterol crystal-induced complement-mediated inflammation:a potential new compound for treatment of atherosclerosis［J］.Atherosclerosis，2019，283:35-42.
［11］ SOEJIMA H，OGAWA H，MORIMOTO T，et al.Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level:subanalysis from the JPAD trial［J］.J Cardiol，2013，62(3):165-170.
［12］ XU S，KAMATO D，LITTLE P J，et al.Targeting epigenetics and non-coding RNAs in atherosclerosis:from mechanisms to therapeutics［J］.Pharmacol Ther，2019,196:15-43.
［13］ ZABIHI N A,MOUSAVI S M,MAHMOUDABADY M,et al.Improves blood glucose and lipids and ameliorates oxidative stress in heart and aorta of diabetic rats［J］.Int J Prev Med,2018，9:110.
［14］ YAMAGISHI S I,MATSUI T.Role of hyperglycemia-induced advanced glycation end product (AGE) accumulation in atherosclerosis［J］.Ann Vasc Dis，2018，11(3):253-258.
［15］ LANKIN V,KONOWALOVA G,TIKHAZE A,et al.The initiation of free radical peroxidation of low-density lipoproteins by glucose and its metabolite methylglyoxal:a common molecular mechanism of vascular wall injure in atherosclerosis and diabetes［J］.Mol Cell Biochem,2014,395(1/2):241-252.
［16］ TEODORO J S,NUNES S,ROLO A P,et al.Therapeutic options targeting oxidative stress，mitochondrial dysfunction and inflammation to hinder the progression of vascular complications of diabetes ［J］.Frontiers in physiology,2018,9:1857.
［17］ YU E P,BENNETT M R.The role of mitochondrial DNA damage in the development of atherosclerosis［J］.Free Radic Biol Med，2016,100:223-230.
［18］ BULLON P，NEWMAN H N,BATTINO M.Obesity，diabetes mellitus，atherosclerosis and chronic periodontitis:a shared pathology via oxidative stress and mitochondrial dysfunction［J］.Periodontol 2000，2014，64(1):139-153.
［19］ ANUPAM K，KAUSHAL J，PRABHAKAR N，et al.Effect of redox status of peripheral blood on immune signature of circulating regulatory and cytotoxic T cells in streptozotocin induced rodent model of type I diabetes［J］.Immunobiology，2018，223(10):586-597.
［20］ BAYRAMI G，ALIHEMMATI A，KARIMI P，et al.Combination of vildagliptin and ischemic postconditioning in diabetic hearts as a working strategy to reduce myocardial reperfusion injury by restoring mitochondrial function and autophagic activity［J］.Adv Pharm Bull，2018，8(2):319-329.
［21］ HE C,HART P C,GERMAIN D.SOD2 and the mitochondrial UPR:partners regulating cellular phenotypic transitions［J］.Trends Biochem Sci,2016,41(7):568-577.
［22］ WANG Q，ZHANG M，TORRES G，et al.Metformin suppresses diabetes-accelerated atherosclerosis via the inhibition of Drp1-mediated mitochondrial fission［J］.Diabetes，2017，66(1):193-205.
［23］ FISHMAN S L，SONMEZ H，BASMAN C，et al.The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus:a review［J］.Mol Med，2018，24(1):59.
［24］ SANTILLI F,D′ARDES D.Oxidative stress in chronic vascular disease:from prediction to prevention ［J］.Vascul Pharmacol,2015,74:23-37.
［25］ BASHAN N，KOVSAN J，KACHKO I，et al.Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species［J］.Physiol Rev，2009，89(1):27-71.
［26］ LUNDBERG J O，GLADWIN M T,WEITZBERG E.Strategies to increase nitric oxide signalling in cardiovascular disease［J］.Nat Rev Drug Discov，2015，14(9):623-641.
［27］ PITOCCO D，ZACCARDI F，DI STASIO E，et al.Oxidative stress， nitric oxide，and diabetes［J］.Rev Diabet Stud，2010，7(1):15-25.
［28］ CAI Z,HE W,ZHUANG F J.The role of high high-sensitivity C-reactive protein levels at admission on poor prognosis after acute ischemic stroke［J］.Int J Neurosci，2019,129(5):423-429.
［29］ LUAN Y Y,YAO Y M.The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases［J］.Front Immunol，2018,9:1302.
［30］ LIBBY P.Interleukin-1 Beta as a target for atherosclerosis therapy:biological basis of CANTOS and beyond［J］.J Am Coll Cardiol,2017,70(18):2278-2289.
［31］ RIDKER P M.From C-Reactive protein to interleukin-6 to interleukin-1:moving upstream to identify novel targets for atheroprotection［J］.Circ Res，2016，118(1):145-156.
［32］ DINARELLO C A.Interleukin-1 in the pathogenesis and treatment of inflammatory diseases［J］.Blood，2011，117(14):3720-3732.
［33］ MOSHAPA F T，RICHES-SUMAN K,PALMER T M.Therapeutic targeting of the proinflammatory IL-6-JAK/STAT signalling pathways responsible for vascular restenosis in type 2 diabetes mellitus［J］.Cardiol Res Pract，2019,2019:9846312.
［34］ TU L,YANG L.IL-33 at the crossroads of metabolic disorders and immunity［J］.Front Endocrinol,2019,10:26.
［35］ ALTARA R,GHALI R,MALLAT Z,et al.Conflicting vascular and metabolic impact of the IL-33/sST2 axis［J］.Cardiovasc Res,2018,114(12):1578-1594.
［36］ SURYAVANSHI S V.NF-κB:a potential target in the management of vascular complications of diabetes［J］.Front Pharmacol,2017,8:798.
［37］ ELKIND M S,TAI W,COATES K,et al.High-sensitivity C-reactive protein，lipoprotein-associated phospholipase A2，and outcome after ischemic stroke［J］.Arch Intern Med,2006,166 (19):2073-2080.
［38］ MORETTI R,CARUSO P.The controversial role of homocysteine in neurology:from labs to clinical practice［J］.Int J Mol Sci，2019，20(1):E231.
［39］ JIALAL I,CHAUDHURI A.Targeting inflammation to reduce ASCVD in type 2 diabetes［J］.J Diabetes Complications，2019，33(1):1-3.
［40］ OREKHOV A N,GRECHKO A V,ROMANENKO E B,et al.Novel approaches to anti-atherosclerotic therapy:cell-based models and herbal preparations (review of our own data)［J］.Curr Drug Discov Technol，2018.DOI:10.2174/157016381666619010111 2241.［Epub ahead of print］.
［41］ PILELY K,BAKKE S S,PALARASAH Y,et al.Alpha-cyclodextrin inhibits cholesterol crystal-induced complement-mediated inflammation:a potential new compound for treatment of atherosclerosis ［J］.Atherosclerosis,2019,283:35-42.
［42］ EILENBERG W,STOJKOVIC S,PIECHOTA-POLANCZYK A,et al.Neutrophil gelatinase associated lipocalin (NGAL) is elevated in type 2 diabetics with carotid artery stenosis and reduced under metformin treatment［J］.Cardiovasc Diabetol,2017,16(1):98.
［43］ FURUHASHI M.Fatty acid-binding protein 4 in cardiovascular and metabolic diseases［J］.J Atheroscler Thromb，2019，26(3):216-232.
［44］ MARLET I R，OLMESTIG J N E，VILSBOLL T，et al.Neuroprotective mechanisms of glucagon-like peptide-1-based therapies in ischaemic stroke:a systematic review based on pre-clinical studies［J］.Basic Clin Pharmacol Toxicol，2018，122(6):559-569.
［45］ VINU E A，MARTINEZ-HERVAS S，HERRERO-CERVERA A，et al.Changes in CDKN2A/2B expression associate with T-cell phenotype modulation in atherosclerosis and type 2 diabetes mellitus［J］.Transl Res，2019,203:31-48.
［46］ PODZOLKOV V I,POKROVSKAYA A E.Vitamin D deficiency and cardiovascular pathology［J］.Ter Arkh,2018,90(9):144-150.
相似文献/References:
[1]马晓军,霍慧春,刘娟,等.针灸联合中药对糖尿病大鼠血脂及血糖的调节作用[J].新乡医学院学报,,():000.
[2]郭永年.糖尿病氯磺丙脲酒精潮红试验[J].新乡医学院学报,1986,3(02):064.
[3]翁孝刚,郭永年,王宪波,等.复方中药渴乐饮对实验大鼠体重及血糖的影响 [J].新乡医学院学报,1994,11(02):107.
[4]郭永年,李灵敏,王伟,等.新光碘蛋的研制及其对糖尿病患者的保健作用 [J].新乡医学院学报,1994,11(04):339.
[5]翁孝刚,王宪波,郭永年,等.复方中药渴乐饮对实验大鼠胰岛B细胞形态及功能的影响[J].新乡医学院学报,1994,11(04):351.
[6]王宪波,翁孝刚,王伟,等.复方中药渴乐饮对实验大鼠的抗氧化抗疲劳作用[J].新乡医学院学报,1994,11(04):354.
[7]翁孝钢,梁荩忠,吴兆锋,等.链脲菌素实验性糖尿病大鼠组织钙调素活性的研究[J].新乡医学院学报,1995,12(03):201.
[8]王宪波,翁孝钢,郭永年,等.复方中药渴乐对实验糖尿病大鼠血脂的影响[J].新乡医学院学报,1995,12(01):018.
[9]王卫民,张清贵,王昕红,等.尿C—肽与Ⅱ型糖尿病患者的β细胞功能[J].新乡医学院学报,1996,13(01):044.
[10]索新华,陈志刚,郭永年,等.糖尿病性水疱病及其感染的临床治疗[J].新乡医学院学报,1997,14(01):057.